Clinical Oncology Next Generation Sequencing-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data
Report Summary
Clinical Oncology Next Generation Sequencing-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data offers a comprehensive analysis on Clinical Oncology Next Generation Sequencing industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Clinical Oncology Next Generation Sequencing 2016-2021, and development forecast 2022-2026
Main manufacturers/suppliers of Clinical Oncology Next Generation Sequencing worldwide and market share by regions, with company and product introduction, position in the Clinical Oncology Next Generation Sequencing market
Market status and development trend of Clinical Oncology Next Generation Sequencing by types and applications
Cost and profit status of Clinical Oncology Next Generation Sequencing, and marketing status
Market growth drivers and challengesSince the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency.The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Clinical Oncology Next Generation Sequencing market in 2020.COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the Clinical Oncology Next Generation Sequencing industry.
The report segments the global Clinical Oncology Next Generation Sequencing market as:
Global Clinical Oncology Next Generation Sequencing Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Clinical Oncology Next Generation Sequencing Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):
Whole Genome Sequencing
Whole Exome Sequencing
Targeted Sequencing & Resequencing Centrifuges
Global Clinical Oncology Next Generation Sequencing Market: Application Segment Analysis (Consumption Volume and Market Share 206-2026; Downstream Customers and Market Analysis)
Hospitals
Clinics
Laboratories
Global Clinical Oncology Next Generation Sequencing Market: Manufacturers Segment Analysis (Company and Product introduction, Clinical Oncology Next Generation Sequencing Sales Volume, Revenue, Price and Gross Margin):
Illumina, Inc.
Thermo Fisher Scientific
F. Hoffmann-La Roche Ltd.
Agilent Technologies
Myriad Genetics
Beijing Genomics Institute (BGI)
Perkin Elmer
Foundation Medicine
Pacific Bioscience
Oxford Nanopore Technologies Ltd.
Paradigm Diagnostics
Caris Life Sciences
Partek, Inc.
Eurofins Scientific S.E.
Qiagen N.V.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Clinical Oncology Next Generation Sequencing-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data offers a comprehensive analysis on Clinical Oncology Next Generation Sequencing industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Clinical Oncology Next Generation Sequencing 2016-2021, and development forecast 2022-2026
Main manufacturers/suppliers of Clinical Oncology Next Generation Sequencing worldwide and market share by regions, with company and product introduction, position in the Clinical Oncology Next Generation Sequencing market
Market status and development trend of Clinical Oncology Next Generation Sequencing by types and applications
Cost and profit status of Clinical Oncology Next Generation Sequencing, and marketing status
Market growth drivers and challengesSince the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency.The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Clinical Oncology Next Generation Sequencing market in 2020.COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the Clinical Oncology Next Generation Sequencing industry.
The report segments the global Clinical Oncology Next Generation Sequencing market as:
Global Clinical Oncology Next Generation Sequencing Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Clinical Oncology Next Generation Sequencing Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):
Whole Genome Sequencing
Whole Exome Sequencing
Targeted Sequencing & Resequencing Centrifuges
Global Clinical Oncology Next Generation Sequencing Market: Application Segment Analysis (Consumption Volume and Market Share 206-2026; Downstream Customers and Market Analysis)
Hospitals
Clinics
Laboratories
Global Clinical Oncology Next Generation Sequencing Market: Manufacturers Segment Analysis (Company and Product introduction, Clinical Oncology Next Generation Sequencing Sales Volume, Revenue, Price and Gross Margin):
Illumina, Inc.
Thermo Fisher Scientific
F. Hoffmann-La Roche Ltd.
Agilent Technologies
Myriad Genetics
Beijing Genomics Institute (BGI)
Perkin Elmer
Foundation Medicine
Pacific Bioscience
Oxford Nanopore Technologies Ltd.
Paradigm Diagnostics
Caris Life Sciences
Partek, Inc.
Eurofins Scientific S.E.
Qiagen N.V.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING
1.1 Definition of Clinical Oncology Next Generation Sequencing in This Report
1.2 Commercial Types of Clinical Oncology Next Generation Sequencing
1.2.1 Whole Genome Sequencing
1.2.2 Whole Exome Sequencing
1.2.3 Targeted Sequencing & Resequencing Centrifuges
1.3 Downstream Application of Clinical Oncology Next Generation Sequencing
1.3.1 Hospitals
1.3.2 Clinics
1.3.3 Laboratories
1.4 Development History of Clinical Oncology Next Generation Sequencing
1.5 Market Status and Trend of Clinical Oncology Next Generation Sequencing 2016-2026
1.5.1 Global Clinical Oncology Next Generation Sequencing Market Status and Trend 2016-2026
1.5.2 Regional Clinical Oncology Next Generation Sequencing Market Status and Trend 2016-2026
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Clinical Oncology Next Generation Sequencing 2016-2021
2.2 Sales Market of Clinical Oncology Next Generation Sequencing by Regions
2.2.1 Sales Volume of Clinical Oncology Next Generation Sequencing by Regions
2.2.2 Sales Value of Clinical Oncology Next Generation Sequencing by Regions
2.3 Production Market of Clinical Oncology Next Generation Sequencing by Regions
2.4 Global Market Forecast of Clinical Oncology Next Generation Sequencing 2022-2026
2.4.1 Global Market Forecast of Clinical Oncology Next Generation Sequencing 2022-2026
2.4.2 Market Forecast of Clinical Oncology Next Generation Sequencing by Regions 2022-2026
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Clinical Oncology Next Generation Sequencing by Types
3.2 Sales Value of Clinical Oncology Next Generation Sequencing by Types
3.3 Market Forecast of Clinical Oncology Next Generation Sequencing by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Clinical Oncology Next Generation Sequencing by Downstream Industry
4.2 Global Market Forecast of Clinical Oncology Next Generation Sequencing by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Clinical Oncology Next Generation Sequencing Market Status by Countries
5.1.1 North America Clinical Oncology Next Generation Sequencing Sales by Countries (2016-2021)
5.1.2 North America Clinical Oncology Next Generation Sequencing Revenue by Countries (2016-2021)
5.1.3 United States Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
5.1.4 Canada Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
5.1.5 Mexico Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
5.2 North America Clinical Oncology Next Generation Sequencing Market Status by Manufacturers
5.3 North America Clinical Oncology Next Generation Sequencing Market Status by Type (2016-2021)
5.3.1 North America Clinical Oncology Next Generation Sequencing Sales by Type (2016-2021)
5.3.2 North America Clinical Oncology Next Generation Sequencing Revenue by Type (2016-2021)
5.4 North America Clinical Oncology Next Generation Sequencing Market Status by Downstream Industry (2016-2021)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Clinical Oncology Next Generation Sequencing Market Status by Countries
6.1.1 Europe Clinical Oncology Next Generation Sequencing Sales by Countries (2016-2021)
6.1.2 Europe Clinical Oncology Next Generation Sequencing Revenue by Countries (2016-2021)
6.1.3 Germany Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
6.1.4 UK Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
6.1.5 France Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
6.1.6 Italy Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
6.1.7 Russia Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
6.1.8 Spain Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
6.1.9 Benelux Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
6.2 Europe Clinical Oncology Next Generation Sequencing Market Status by Manufacturers
6.3 Europe Clinical Oncology Next Generation Sequencing Market Status by Type (2016-2021)
6.3.1 Europe Clinical Oncology Next Generation Sequencing Sales by Type (2016-2021)
6.3.2 Europe Clinical Oncology Next Generation Sequencing Revenue by Type (2016-2021)
6.4 Europe Clinical Oncology Next Generation Sequencing Market Status by Downstream Industry (2016-2021)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Clinical Oncology Next Generation Sequencing Market Status by Countries
7.1.1 Asia Pacific Clinical Oncology Next Generation Sequencing Sales by Countries (2016-2021)
7.1.2 Asia Pacific Clinical Oncology Next Generation Sequencing Revenue by Countries (2016-2021)
7.1.3 China Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
7.1.4 Japan Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
7.1.5 India Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
7.1.6 Southeast Asia Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
7.1.7 Australia Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
7.2 Asia Pacific Clinical Oncology Next Generation Sequencing Market Status by Manufacturers
7.3 Asia Pacific Clinical Oncology Next Generation Sequencing Market Status by Type (2016-2021)
7.3.1 Asia Pacific Clinical Oncology Next Generation Sequencing Sales by Type (2016-2021)
7.3.2 Asia Pacific Clinical Oncology Next Generation Sequencing Revenue by Type (2016-2021)
7.4 Asia Pacific Clinical Oncology Next Generation Sequencing Market Status by Downstream Industry (2016-2021)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Clinical Oncology Next Generation Sequencing Market Status by Countries
8.1.1 Latin America Clinical Oncology Next Generation Sequencing Sales by Countries (2016-2021)
8.1.2 Latin America Clinical Oncology Next Generation Sequencing Revenue by Countries (2016-2021)
8.1.3 Brazil Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
8.1.4 Argentina Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
8.1.5 Colombia Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
8.2 Latin America Clinical Oncology Next Generation Sequencing Market Status by Manufacturers
8.3 Latin America Clinical Oncology Next Generation Sequencing Market Status by Type (2016-2021)
8.3.1 Latin America Clinical Oncology Next Generation Sequencing Sales by Type (2016-2021)
8.3.2 Latin America Clinical Oncology Next Generation Sequencing Revenue by Type (2016-2021)
8.4 Latin America Clinical Oncology Next Generation Sequencing Market Status by Downstream Industry (2016-2021)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Clinical Oncology Next Generation Sequencing Market Status by Countries
9.1.1 Middle East and Africa Clinical Oncology Next Generation Sequencing Sales by Countries (2016-2021)
9.1.2 Middle East and Africa Clinical Oncology Next Generation Sequencing Revenue by Countries (2016-2021)
9.1.3 Middle East Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
9.1.4 Africa Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
9.2 Middle East and Africa Clinical Oncology Next Generation Sequencing Market Status by Manufacturers
9.3 Middle East and Africa Clinical Oncology Next Generation Sequencing Market Status by Type (2016-2021)
9.3.1 Middle East and Africa Clinical Oncology Next Generation Sequencing Sales by Type (2016-2021)
9.3.2 Middle East and Africa Clinical Oncology Next Generation Sequencing Revenue by Type (2016-2021)
9.4 Middle East and Africa Clinical Oncology Next Generation Sequencing Market Status by Downstream Industry (2016-2021)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING
10.1 Global Economy Situation and Trend Overview
10.2 Clinical Oncology Next Generation Sequencing Downstream Industry Situation and Trend Overview
CHAPTER 11 CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Clinical Oncology Next Generation Sequencing by Major Manufacturers
11.2 Production Value of Clinical Oncology Next Generation Sequencing by Major Manufacturers
11.3 Basic Information of Clinical Oncology Next Generation Sequencing by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Clinical Oncology Next Generation Sequencing Major Manufacturer
11.3.2 Employees and Revenue Level of Clinical Oncology Next Generation Sequencing Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Illumina, Inc.
12.1.1 Company profile
12.1.2 Representative Clinical Oncology Next Generation Sequencing Product
12.1.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Illumina, Inc.
12.2 Thermo Fisher Scientific
12.2.1 Company profile
12.2.2 Representative Clinical Oncology Next Generation Sequencing Product
12.2.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Thermo Fisher Scientific
12.3 F. Hoffmann-La Roche Ltd.
12.3.1 Company profile
12.3.2 Representative Clinical Oncology Next Generation Sequencing Product
12.3.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd.
12.4 Agilent Technologies
12.4.1 Company profile
12.4.2 Representative Clinical Oncology Next Generation Sequencing Product
12.4.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Agilent Technologies
12.5 Myriad Genetics
12.5.1 Company profile
12.5.2 Representative Clinical Oncology Next Generation Sequencing Product
12.5.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Myriad Genetics
12.6 Beijing Genomics Institute (BGI)
12.6.1 Company profile
12.6.2 Representative Clinical Oncology Next Generation Sequencing Product
12.6.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Beijing Genomics Institute (BGI)
12.7 Perkin Elmer
12.7.1 Company profile
12.7.2 Representative Clinical Oncology Next Generation Sequencing Product
12.7.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Perkin Elmer
12.8 Foundation Medicine
12.8.1 Company profile
12.8.2 Representative Clinical Oncology Next Generation Sequencing Product
12.8.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Foundation Medicine
12.9 Pacific Bioscience
12.9.1 Company profile
12.9.2 Representative Clinical Oncology Next Generation Sequencing Product
12.9.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Pacific Bioscience
12.10 Oxford Nanopore Technologies Ltd.
12.10.1 Company profile
12.10.2 Representative Clinical Oncology Next Generation Sequencing Product
12.10.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Oxford Nanopore Technologies Ltd.
12.11 Paradigm Diagnostics
12.11.1 Company profile
12.11.2 Representative Clinical Oncology Next Generation Sequencing Product
12.11.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Paradigm Diagnostics
12.12 Caris Life Sciences
12.12.1 Company profile
12.12.2 Representative Clinical Oncology Next Generation Sequencing Product
12.12.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Caris Life Sciences
12.13 Partek, Inc.
12.13.1 Company profile
12.13.2 Representative Clinical Oncology Next Generation Sequencing Product
12.13.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Partek, Inc.
12.14 Eurofins Scientific S.E.
12.14.1 Company profile
12.14.2 Representative Clinical Oncology Next Generation Sequencing Product
12.14.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Eurofins Scientific S.E.
12.15 Qiagen N.V.
12.15.1 Company profile
12.15.2 Representative Clinical Oncology Next Generation Sequencing Product
12.15.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Qiagen N.V.
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING
13.1 Industry Chain of Clinical Oncology Next Generation Sequencing
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING
14.1 Cost Structure Analysis of Clinical Oncology Next Generation Sequencing
14.2 Raw Materials Cost Analysis of Clinical Oncology Next Generation Sequencing
14.3 Labor Cost Analysis of Clinical Oncology Next Generation Sequencing
14.4 Manufacturing Expenses Analysis of Clinical Oncology Next Generation Sequencing
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Clinical Oncology Next Generation Sequencing in This Report
1.2 Commercial Types of Clinical Oncology Next Generation Sequencing
1.2.1 Whole Genome Sequencing
1.2.2 Whole Exome Sequencing
1.2.3 Targeted Sequencing & Resequencing Centrifuges
1.3 Downstream Application of Clinical Oncology Next Generation Sequencing
1.3.1 Hospitals
1.3.2 Clinics
1.3.3 Laboratories
1.4 Development History of Clinical Oncology Next Generation Sequencing
1.5 Market Status and Trend of Clinical Oncology Next Generation Sequencing 2016-2026
1.5.1 Global Clinical Oncology Next Generation Sequencing Market Status and Trend 2016-2026
1.5.2 Regional Clinical Oncology Next Generation Sequencing Market Status and Trend 2016-2026
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Clinical Oncology Next Generation Sequencing 2016-2021
2.2 Sales Market of Clinical Oncology Next Generation Sequencing by Regions
2.2.1 Sales Volume of Clinical Oncology Next Generation Sequencing by Regions
2.2.2 Sales Value of Clinical Oncology Next Generation Sequencing by Regions
2.3 Production Market of Clinical Oncology Next Generation Sequencing by Regions
2.4 Global Market Forecast of Clinical Oncology Next Generation Sequencing 2022-2026
2.4.1 Global Market Forecast of Clinical Oncology Next Generation Sequencing 2022-2026
2.4.2 Market Forecast of Clinical Oncology Next Generation Sequencing by Regions 2022-2026
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Clinical Oncology Next Generation Sequencing by Types
3.2 Sales Value of Clinical Oncology Next Generation Sequencing by Types
3.3 Market Forecast of Clinical Oncology Next Generation Sequencing by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Clinical Oncology Next Generation Sequencing by Downstream Industry
4.2 Global Market Forecast of Clinical Oncology Next Generation Sequencing by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Clinical Oncology Next Generation Sequencing Market Status by Countries
5.1.1 North America Clinical Oncology Next Generation Sequencing Sales by Countries (2016-2021)
5.1.2 North America Clinical Oncology Next Generation Sequencing Revenue by Countries (2016-2021)
5.1.3 United States Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
5.1.4 Canada Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
5.1.5 Mexico Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
5.2 North America Clinical Oncology Next Generation Sequencing Market Status by Manufacturers
5.3 North America Clinical Oncology Next Generation Sequencing Market Status by Type (2016-2021)
5.3.1 North America Clinical Oncology Next Generation Sequencing Sales by Type (2016-2021)
5.3.2 North America Clinical Oncology Next Generation Sequencing Revenue by Type (2016-2021)
5.4 North America Clinical Oncology Next Generation Sequencing Market Status by Downstream Industry (2016-2021)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Clinical Oncology Next Generation Sequencing Market Status by Countries
6.1.1 Europe Clinical Oncology Next Generation Sequencing Sales by Countries (2016-2021)
6.1.2 Europe Clinical Oncology Next Generation Sequencing Revenue by Countries (2016-2021)
6.1.3 Germany Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
6.1.4 UK Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
6.1.5 France Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
6.1.6 Italy Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
6.1.7 Russia Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
6.1.8 Spain Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
6.1.9 Benelux Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
6.2 Europe Clinical Oncology Next Generation Sequencing Market Status by Manufacturers
6.3 Europe Clinical Oncology Next Generation Sequencing Market Status by Type (2016-2021)
6.3.1 Europe Clinical Oncology Next Generation Sequencing Sales by Type (2016-2021)
6.3.2 Europe Clinical Oncology Next Generation Sequencing Revenue by Type (2016-2021)
6.4 Europe Clinical Oncology Next Generation Sequencing Market Status by Downstream Industry (2016-2021)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Clinical Oncology Next Generation Sequencing Market Status by Countries
7.1.1 Asia Pacific Clinical Oncology Next Generation Sequencing Sales by Countries (2016-2021)
7.1.2 Asia Pacific Clinical Oncology Next Generation Sequencing Revenue by Countries (2016-2021)
7.1.3 China Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
7.1.4 Japan Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
7.1.5 India Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
7.1.6 Southeast Asia Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
7.1.7 Australia Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
7.2 Asia Pacific Clinical Oncology Next Generation Sequencing Market Status by Manufacturers
7.3 Asia Pacific Clinical Oncology Next Generation Sequencing Market Status by Type (2016-2021)
7.3.1 Asia Pacific Clinical Oncology Next Generation Sequencing Sales by Type (2016-2021)
7.3.2 Asia Pacific Clinical Oncology Next Generation Sequencing Revenue by Type (2016-2021)
7.4 Asia Pacific Clinical Oncology Next Generation Sequencing Market Status by Downstream Industry (2016-2021)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Clinical Oncology Next Generation Sequencing Market Status by Countries
8.1.1 Latin America Clinical Oncology Next Generation Sequencing Sales by Countries (2016-2021)
8.1.2 Latin America Clinical Oncology Next Generation Sequencing Revenue by Countries (2016-2021)
8.1.3 Brazil Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
8.1.4 Argentina Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
8.1.5 Colombia Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
8.2 Latin America Clinical Oncology Next Generation Sequencing Market Status by Manufacturers
8.3 Latin America Clinical Oncology Next Generation Sequencing Market Status by Type (2016-2021)
8.3.1 Latin America Clinical Oncology Next Generation Sequencing Sales by Type (2016-2021)
8.3.2 Latin America Clinical Oncology Next Generation Sequencing Revenue by Type (2016-2021)
8.4 Latin America Clinical Oncology Next Generation Sequencing Market Status by Downstream Industry (2016-2021)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Clinical Oncology Next Generation Sequencing Market Status by Countries
9.1.1 Middle East and Africa Clinical Oncology Next Generation Sequencing Sales by Countries (2016-2021)
9.1.2 Middle East and Africa Clinical Oncology Next Generation Sequencing Revenue by Countries (2016-2021)
9.1.3 Middle East Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
9.1.4 Africa Clinical Oncology Next Generation Sequencing Market Status (2016-2021)
9.2 Middle East and Africa Clinical Oncology Next Generation Sequencing Market Status by Manufacturers
9.3 Middle East and Africa Clinical Oncology Next Generation Sequencing Market Status by Type (2016-2021)
9.3.1 Middle East and Africa Clinical Oncology Next Generation Sequencing Sales by Type (2016-2021)
9.3.2 Middle East and Africa Clinical Oncology Next Generation Sequencing Revenue by Type (2016-2021)
9.4 Middle East and Africa Clinical Oncology Next Generation Sequencing Market Status by Downstream Industry (2016-2021)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING
10.1 Global Economy Situation and Trend Overview
10.2 Clinical Oncology Next Generation Sequencing Downstream Industry Situation and Trend Overview
CHAPTER 11 CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Clinical Oncology Next Generation Sequencing by Major Manufacturers
11.2 Production Value of Clinical Oncology Next Generation Sequencing by Major Manufacturers
11.3 Basic Information of Clinical Oncology Next Generation Sequencing by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Clinical Oncology Next Generation Sequencing Major Manufacturer
11.3.2 Employees and Revenue Level of Clinical Oncology Next Generation Sequencing Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Illumina, Inc.
12.1.1 Company profile
12.1.2 Representative Clinical Oncology Next Generation Sequencing Product
12.1.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Illumina, Inc.
12.2 Thermo Fisher Scientific
12.2.1 Company profile
12.2.2 Representative Clinical Oncology Next Generation Sequencing Product
12.2.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Thermo Fisher Scientific
12.3 F. Hoffmann-La Roche Ltd.
12.3.1 Company profile
12.3.2 Representative Clinical Oncology Next Generation Sequencing Product
12.3.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd.
12.4 Agilent Technologies
12.4.1 Company profile
12.4.2 Representative Clinical Oncology Next Generation Sequencing Product
12.4.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Agilent Technologies
12.5 Myriad Genetics
12.5.1 Company profile
12.5.2 Representative Clinical Oncology Next Generation Sequencing Product
12.5.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Myriad Genetics
12.6 Beijing Genomics Institute (BGI)
12.6.1 Company profile
12.6.2 Representative Clinical Oncology Next Generation Sequencing Product
12.6.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Beijing Genomics Institute (BGI)
12.7 Perkin Elmer
12.7.1 Company profile
12.7.2 Representative Clinical Oncology Next Generation Sequencing Product
12.7.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Perkin Elmer
12.8 Foundation Medicine
12.8.1 Company profile
12.8.2 Representative Clinical Oncology Next Generation Sequencing Product
12.8.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Foundation Medicine
12.9 Pacific Bioscience
12.9.1 Company profile
12.9.2 Representative Clinical Oncology Next Generation Sequencing Product
12.9.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Pacific Bioscience
12.10 Oxford Nanopore Technologies Ltd.
12.10.1 Company profile
12.10.2 Representative Clinical Oncology Next Generation Sequencing Product
12.10.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Oxford Nanopore Technologies Ltd.
12.11 Paradigm Diagnostics
12.11.1 Company profile
12.11.2 Representative Clinical Oncology Next Generation Sequencing Product
12.11.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Paradigm Diagnostics
12.12 Caris Life Sciences
12.12.1 Company profile
12.12.2 Representative Clinical Oncology Next Generation Sequencing Product
12.12.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Caris Life Sciences
12.13 Partek, Inc.
12.13.1 Company profile
12.13.2 Representative Clinical Oncology Next Generation Sequencing Product
12.13.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Partek, Inc.
12.14 Eurofins Scientific S.E.
12.14.1 Company profile
12.14.2 Representative Clinical Oncology Next Generation Sequencing Product
12.14.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Eurofins Scientific S.E.
12.15 Qiagen N.V.
12.15.1 Company profile
12.15.2 Representative Clinical Oncology Next Generation Sequencing Product
12.15.3 Clinical Oncology Next Generation Sequencing Sales, Revenue, Price and Gross Margin of Qiagen N.V.
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING
13.1 Industry Chain of Clinical Oncology Next Generation Sequencing
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING
14.1 Cost Structure Analysis of Clinical Oncology Next Generation Sequencing
14.2 Raw Materials Cost Analysis of Clinical Oncology Next Generation Sequencing
14.3 Labor Cost Analysis of Clinical Oncology Next Generation Sequencing
14.4 Manufacturing Expenses Analysis of Clinical Oncology Next Generation Sequencing
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
